TABLE 1.
Laboratory findings
| (March 2018) | ALT 7 U/L | Anti‐RNP Ab (−) | Arterial blood gas (room air) |
| Hematology | T‐bil 0.8 mg/dL | Anti‐ARS Ab (−) | pH 7.434 |
| WBC 7500/μL | LDH 176 U/L | MPO‐ANCA (−) | PaCO2 34.6 Torr |
| Neu 46.6% | CK 56 U/L | PR3‐ANCA 5.8 U/mL | PaO2 71.5 Torr |
| Lym 40.4% | Glu 166 mg/dL | HCO3 −24.0 nmol/L | |
| Mono 6.1% | HbA1c 8.4% | Urinalysis | |
| Eos 5.6% | CRP 0.11 mg/dL | Urine protein (−) | Pulmonary function (% predicted) |
| Baso 1. % | KL‐6583 U/mL | Urine OB (±) | VC 3.49 L (115.9%) |
| RBC 4.64 × 106/μL | SP‐D 228 ng/mL | Urine glucose (−) | FVC 3.45 L (118.1%) |
| Hb 14.9 g/dL | β‐D‐glucan (−) | FEV1 2.81 L (126.0%) | |
| PLT 15.5 × 104/μL | (April 2019) | FEV1/FVC 81.44% | |
| Immunology | Tumor marker | DLCO 8.95 mL/min/mm Hg (69.6%) | |
| Blood chemistry | ANA × 80 | CEA 4.04 ng/mL | DLCO/VA2.42 mL/min/mm Hg/L (60.6%) |
| TP 7.46 g/dL | Homogeneous (+) | CYFRA 3.5 ng/mL | |
| Alb 3.74 g/dL | Speckled (+) | ProGRP 45.3 pg/mL | 6‐min walking test (room air) |
| BUN 13.8 mg/dL | Ant‐CCP Ab (−) | SpO2 94% → 84% | |
| Cre 0.79 mg/dL | Anti‐SS‐A Ab (−) | Total distance 520 m | |
| AST 15 U/L | Anti‐SS‐B Ab (−) |
Abbreviations: Ab, antibody; ANA, anti‐nuclear antibody; ARS, aminoacyl‐tRNA synthetase; CCP, cyclic citrullinated peptide; CEA, carcinoembryonic antigen; CYFRA, cytokeratin fragment; DLco, diffusing capacity for carbon monoxide; FEV1, forced expiratory volume 1; FVC, forced vital capacity; MPO‐ANCA, myeroperoxidase‐antineutrophil cytoplasmic antibody; PR3‐ANCA, proteinase3‐antineutrophil cytoplasmic antibody; ProGRP, pro‐gastrin‐releasing peptide; RNP, ribonucleoprotein; SP‐D, surfactant protein‐D; SS‐A, Sjögren's‐syndrome‐related antigen‐A; SS‐B, Sjögren's‐syndrome‐related antigen‐B; VA, alveolar volume; VC, vital capacity.